4.7 Review

COX-2 inhibitors: a novel strategy in the management of breast cancer

Journal

DRUG DISCOVERY TODAY
Volume 21, Issue 4, Pages 598-615

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2015.12.003

Keywords

-

Funding

  1. National Science Centre (NCN) of Poland [UMO-2011/01/N/NZ4/01137]

Ask authors/readers for more resources

Cyclooxygenase-2 (COX-2) inhibitors are common anti-inflammatory drugs with pleiotropic, endogenous actions that could be useful in the management of breast cancer. Here, we provide a complete understanding of the biochemistry of COX-2 and discuss the various molecular mechanisms behind its increased expression in breast cancer. We also analyze the possible mechanisms responsible for the anticancer effect of COX-2 inhibitors and provide an overview of the available preclinical and clinical data on the use of COX-2 inhibitors in breast cancer. Finally, we describe a mathematical model of the relation between the structure and biological potency of promising new COX-2 inhibitors (trans-stilbenes) using a 2D quantitative structure-activity relationship (QSAR) technique.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available